Valuation : Altimmune, Inc.

Market Cap 652M 560M 529M 482M 900M 62.3B 909M 6.3B 2.42B 31.6B 2.45B 2.39B 100B P/E 2026 *
-5.72x
P/E 2027 * -5.11x
Enterprise Value 211M 182M 171M 156M 292M 20.19B 294M 2.04B 785M 10.24B 793M 776M 32.52B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
99.58%
Yield 2026 *
-
Yield 2027 * -
1 day-1.79%
1 week+1.86%
Current month+5.79%
1 month+7.87%
3 months+26.05%
6 months-14.77%
Current year-8.86%
1 week 3.25
Extreme 3.25
3.55
1 month 2.84
Extreme 2.84
3.55
Current year 2.56
Extreme 2.56
6.44
1 year 2.56
Extreme 2.56
6.44
3 years 2.09
Extreme 2.09
14.84
5 years 2.09
Extreme 2.09
23.49
10 years 1.51
Extreme 1.51
237.3
Manager TitleAgeSince
Chief Executive Officer 58 01/01/2026
Director of Finance/CFO 70 11/11/2024
Chief Tech/Sci/R&D Officer - 01/05/2025
Director TitleAgeSince
Director/Board Member 58 01/09/2003
Chairman 78 01/01/2018
Director/Board Member 76 01/07/2012
Date Insider Type Main position Quantity % Market Cap. Importance
8/13/26 A Buy

Chief Executive Officer

15,000 0.0077%
7/31/26 A Free

Chief Financial Officer

1,753 0.0009%
7/31/26 A Free

Chief Technology Officer

875 0.0004%
Change 5-day change 1-year change 3-year change Capi.($)
-1.79%+1.86%-10.35%+35.39% 652M
-0.25%-0.96%+45.25%+102.76% 68.52B
-1.09%-4.97%+31.10%+76.56% 62.88B
-1.18%+0.47%-12.78%+380.30% 28.13B
-2.74%-3.53%+26.13%+13.50% 25.56B
-1.76%-6.30%-4.55%-18.27% 24.65B
-2.39%-4.23%+18.42%-20.95% 19.81B
-1.86%+1.15%+205.44%+353.89% 17.69B
-1.37%-3.77%-9.38%+528.34% 14.66B
-1.54%-2.88%+52.33%+161.16% 14.45B
Average -1.60%-0.32%+34.16%+161.27% 27.7B
Weighted average by Cap. -1.29%-1.38%+35.61%+138.59%

Financials

2026 *2027 *
Net sales - -
Net income -100M -86.42M -81.54M -74.28M -139M -9.61B -140M -971M -374M -4.87B -377M -369M -15.48B -123M -106M -99.93M -91.03M -170M -11.77B -172M -1.19B -458M -5.97B -462M -452M -18.97B
Net Debt -440M -379M -357M -326M -609M -42.12B -614M -4.26B -1.64B -21.36B -1.65B -1.62B -67.85B -332M -285M -269M -245M -458M -31.71B -463M -3.21B -1.23B -16.09B -1.25B -1.22B -51.09B
Logo Altimmune, Inc.
Altimmune, Inc. is a late clinical-stage biopharmaceutical company. The Company is developing novel therapies for serious liver diseases. Its lead product candidate, pemvidutide (formerly ALT-801), is a balanced 1:1 glucagon/GLP-1 dual receptor agonist in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD) and alcohol-associated liver disease (ALD). The activation of glucagon receptors results in direct effects on the liver, including reductions in liver fat, inflammation and fibrosis, whereas the activation of GLP-1 receptors mediates suppression of appetite and reduction of cravings as well as metabolic effects such as weight loss. It has completed phase II development of pemvidutide. It also develops and commercializes surfactant-functionalized (EuPort domain) incretin-based peptide therapeutics, including (GLP-1-glucagon)/oxyntomodulin, and variants.
Employees
57
Date Price Change Volume
10/09/26 $3.290 -1.79% 2,542,676
09/09/26 $3.350 -0.30% 3,076,359
08/09/26 $3.360 -1.75% 3,591,744
04/09/26 $3.420 +5.88% 4,871,948
03/09/26 $3.230 -1.52% 2,552,090
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
3.350USD
Average target price
17.22USD
Spread / Average Target
+414.10%

Quarterly revenue - Rate of surprise

40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!